Don't worry, this post is spoiler-free.

Blake Crouch wrote a popular science-fiction thriller novel that is just screaming for a Hollywood adaptation. So, what's the ...

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...

The Kelp DAO exploit was not simply a bridge failure. A forged cross-chain message created phantom rsETH, but the larger shock came from where those tokens went next: into Aave as collateral, where ...

That brings us to Recursion Pharmaceuticals (RXRX +3.86%), a biotech company specializing in drug discovery using artificial intelligence (AI). At least one notable name in the investing world thinks ...

This was largely due to news from a rival clincal-stage biotech. Late on Friday, U.K.-based Biodexa announced it had launched a phase 3 clinical trial of its eRapa, an investigational drug that ...

Recursion Pharmaceuticals (RXRX) shares soared 5.8% in the last trading session to close at $5.84. The move was backed by solid volume with far more shares changing hands than in a normal session.

Through the funding and collaboration with Nvidia, Recursion plans to develop new AI models for drug discovery on the Nvidia DGX Cloud—billed as “AI-training-as-a-service” software. (iambuff/ ...